Trial Condition(s):

Prevention of oesophagus cancer and stomach cancer

EffectiveNess of low-dose Aspirin in prevention of cancer in the stomach and oesophagus (GastrointEstinal cancer prevention) – United Kingdom (“ENgAGE – UK”): Study to evaluate the risk of cancer in the stomach and oesophagus among new users of low-dose Aspirin using the THIN database in the UK (ENgAGE–UK)

Bayer Identifier:

20326

ClinicalTrials.gov Identifier:

NCT03743883

EudraCT Number:

Not Available

Study Completed

Trial Purpose

Researchers already did studies in low-dose Aspirin for the prevention of heart and blood vessels disease and for the prevention of cancer of the colorectum. In this study, they want to learn whether an effect for the prevention of oesophagus cancer and stomach cancer goes along with the use of low-dose ASA on patients taking this medicine for the prevention of heart and blood vessels disease compared to non-use. To find this out electronic medical records stored in primary care database in the UK, The Health Improvement Network (THIN), will be used.

Inclusion Criteria
- Aged 40-89 years
- Enrolled with the PCP for at least 2 years
- To have a history of computerized prescriptions in THIN for at least 1 year prior to start date
Exclusion Criteria
- To be exposed to low-dose ASA before entering in the study
- Having a diagnosis of any cancer before entering in the study

Trial Summary

Enrollment Goal
99999
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Aspirin (Acetylsalicylic Acid, BAYE4465)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Many locations

Many locations, United Kingdom

Status
Completed
 

Trial Design